Co-Diagnostics, Inc. Comprehensive Income
Co-Diagnostics, Inc. (CODX) reported Comprehensive Income of -$6.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$6.28M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$9.14M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$25.84M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$5.93M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$47.31M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$37.37M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$35.48M.
- Co-Diagnostics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$13.95M, a 138.04% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.28M 10-Q · filed 2026-08-13 | -$15.42M 10-Q · filed 2026-08-13 | -$41.26M derived: sum of 3 quarters · filed 2026-08-13 | -$47.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$9.14M 10-Q · filed 2026-05-14 | -$34.98M derived: sum of 2 quarters · filed 2026-05-14 | -$40.91M derived: sum of 3 quarters · filed 2026-05-14 | -$48.83M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$25.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$31.77M derived: sum of 2 quarters · filed 2026-03-31 | -$39.69M derived: sum of 3 quarters · filed 2026-08-13 | -$47.31M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$5.93M 10-Q · filed 2025-11-13 | -$13.85M derived: sum of 2 quarters · filed 2026-08-13 | -$21.47M 10-Q · filed 2025-11-13 | -$32.49M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$7.93M 10-Q · filed 2026-08-13 | -$15.55M 10-Q · filed 2026-08-13 | -$26.57M derived: sum of 3 quarters · filed 2026-08-13 | -$36.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$7.62M 10-Q · filed 2026-05-14 | -$18.64M derived: sum of 2 quarters · filed 2026-05-14 | -$28.30M derived: sum of 3 quarters · filed 2026-05-14 | -$35.76M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$11.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$20.68M derived: sum of 2 quarters · filed 2026-03-31 | -$28.14M derived: sum of 3 quarters · filed 2026-03-31 | -$37.37M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$9.66M 10-Q · filed 2025-11-13 | -$17.11M derived: sum of 2 quarters · filed 2025-11-13 | -$26.35M 10-Q · filed 2025-11-13 | -$41.49M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$7.45M 10-Q · filed 2025-08-14 | -$16.69M 10-Q · filed 2025-08-14 | -$31.83M derived: sum of 3 quarters · filed 2025-08-14 | -$37.78M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$9.23M 10-Q · filed 2025-05-08 | -$24.37M derived: sum of 2 quarters · filed 2025-05-08 | -$30.32M derived: sum of 3 quarters · filed 2025-05-08 | -$39.13M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$21.09M derived: sum of 2 quarters · filed 2025-03-27 | -$29.90M derived: sum of 3 quarters · filed 2025-03-27 | -$35.48M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$5.95M 10-Q · filed 2024-11-07 | -$14.76M derived: sum of 2 quarters · filed 2024-11-07 | -$20.34M 10-Q · filed 2024-11-07 | -$41.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$8.81M 10-Q · filed 2024-08-08 | -$14.39M 10-Q · filed 2024-08-08 | -$36.00M derived: sum of 3 quarters · filed 2024-08-08 | -$37.36M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$5.58M 10-Q · filed 2024-05-09 | -$27.19M derived: sum of 2 quarters · filed 2024-05-09 | -$28.55M derived: sum of 3 quarters · filed 2024-05-09 | -$31.24M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$21.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$22.97M derived: sum of 2 quarters · filed 2024-03-14 | -$25.66M derived: sum of 3 quarters · filed 2024-03-14 | -$13.95M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$1.36M 10-Q · filed 2023-11-09 | -$4.05M derived: sum of 2 quarters · filed 2023-11-09 | $7.67M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$2.69M 10-Q · filed 2023-08-10 | $9.03M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $11.71M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $36.66M 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B | |
| AETHLON MEDICAL INC (AEMD) | United States | $0.005B | |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |